GIMBHI: AtaiBeckley Q1 2026 Earnings

Uncategorized

May 14

Written By

atai Life Sciences + Beckley Psytech closed strategic combination Nov 5, 2025
Two most prominent independent psychedelic biotech platforms consolidated into one Nasdaq vehicle (ATAI)
Redomiciled Netherlands → Luxembourg → Delaware on Dec 30, 2025
Repositioned as US capital markets story, not European science project
The category is now structurally a two-horse race in public markets (ATAI vs COMPASS)

Revenue $0.95M (down 39% YoY, entirely from Nualtis subsidiary, not core assets)
R&D $17.4M (up 54% YoY)
G&A $14.4M (up 36% YoY, driven by $3.2M legal/IP/professional fees)
Q1 net loss $29.8M
Accumulated deficit $1.4B (over a billion cumulative spend to reach registrational stage)
Stock-based comp $5.4M in Q1 (annualizing ~$22M)
$68.6M unrecognized SBC over ~3.1 years (not tapering soon)
$209.9M cash + short-term securities
Zero debt (Hercules term loan paid off May 2025 for $21.8M + fees)
Runway guided “into 2029”

BPL-003 (mebufotenin / 5-MeO-DMT nasal spray for TRD): FDA Breakthrough Therapy, Phase 3 Q2 2026, topline early 2029
Phase 3 program: ReConnection-1 (~350 patients) + ReConnection-2 (~230 patients)
MADRS Week 4 primary endpoint; 52-week extensions test 8 vs 12-week retreatment intervals
Retreatment cadence is the commercial question for the entire interventional psychiatry category
VLS-01 (DMT buccal film for TRD): Elumina Phase 2 topline expected Q4 2026, next near-term catalyst
EMP-01 (oral R-MDMA for SAD): Phase 2a complete with “clinically meaningful” improvements
R-enantiomer angle could fill the vacuum left by Lykos’s MDMA-for-PTSD CRL with cleaner safety
Non-hallucinogenic 5-HT2A agonists (discovery): the hedge if REMS-heavy psychedelics don’t work at scale
Q1 program spend: VLS-01 $5.5M, BPL-003 $2.5M, EMP-01 $1.7M

Closed Nov 5, 2025; atai issued 103.8M shares + replacement RSUs/options + $5.3M cash
Total consideration $519.6M (including atai’s previously-held $53.9M Beckley stake)
Accounted for as asset acquisition, not business combination
$527M allocated to acquired IPR&D, immediately written off as R&D expense Q4 2025
This is why accumulated deficit jumped $700M → $1.4B in 2025 (mostly non-cash IPR&D charge)
Beckley’s ELE-101 IV psilocin spun out into Amandala Neuro pre-close (atai owns 33.7%, no board seats, zero carrying value)
~10.2M shares under 12-month lock-up releasing 1/12 monthly through January 2027 (steady supply overhang)
Merger structurally removed atai’s main psychedelic competitor

Feb 2025: 30.1M shares at $2.10, $59.1M net
June 2025 PIPE: $29.9M at $1.84 (with pre-funded warrants)
July 2025 PIPE: $50.0M at $2.19 (with pre-funded warrants)
Oct 2025: 27.3M shares at $5.48, $139.1M net (stock more than doubled between PIPEs and Oct raise)
That’s the moment capital markets started underwriting the combined company
ATM facility with Jefferies put in place March 6, 2026 (zero sales through Q1)
Pre-funded warrant liabilities $38.4M, mark to stock price, generated $6.0M non-cash gain in Q1
365.6M shares outstanding vs 199.8M YoY (up ~83%)

COMPASS Pathways stake reduced $35.4M → $20.9M via 1.35M ADS sold at $6.92 avg
Using a competitor’s stock to fund your trials is one of the more creative non-dilutive plays in biotech
Bitcoin holding ~100 BTC ($6.8M at Q1 end, marked down $2.0M in Q1)
Christian Angermayer signature move more than a treasury strategy
NIDA grant up to $11.4M over multiple years for non-hallucinogenic 5-HT2A discovery
$0.6M recognized in Q1 as R&D expense reduction
Psilera DMT patent portfolio acquired Feb 2025 ($0.8M upfront + $2.3M milestone paid Aug 2025)
Up to $80M in sales milestones outstanding (IP-stacking continues)

~25% workforce reduction March 2025 + another ~10% November 2025 (two cuts in nine months)
Combined cash cost ~$2.9M for severance, mostly paid out
“Other programs” R&D spend down $2.7M YoY
RL-007 (schizophrenia cognitive impairment) and IBX-210 wound down
Platform being pruned, not expanded
Pre-Beckley atai was a holding company with too many bets; post-Beckley it’s three focused Phase 2/3 assets

Christian Angermayer’s Apeiron family office owns 15.1% (confidence signal + key-person risk)
New Consultancy Agreement extends Angermayer’s role through January 2028
June 2025 option grants to Angermayer: 630K options with asset-value-goal performance hurdles
Performance criteria tied to valuation targets by Dec 31, 2026
COO Gerd Kochendoerfer adopted 10b5-1 plan March 2026 for up to 875K shares through Sept 2027

Zero revenue from any core asset; doesn’t expect any “for at least the next several years”
Binary equity story until Phase 3 readouts
Q1 operating burn $21.1M + investing burn $21.7M (mostly Treasury purchases)
True operating cash burn closer to $25-30M/quarter
$210M cash funds ~7-8 quarters at that burn rate
“Into 2029” runway assumes burn doesn’t escalate as Phase 3 ramps (optimistic)
No commercial infrastructure, no sales force, no payor relationships
If BPL-003 hits in 2029, must build commercial from scratch or partner

COMPASS Pathways trading at market cap that justifies $20.9M for atai’s residual stake
Entire psychedelic-for-depression public market is small and correlated; one Phase 3 failure could re-rate the whole category
Talkspace/UHS deal + Beckley/atai merger in same quarter
Mental health consolidating at both ends of the stack: service delivery and therapeutic development
Lykos’s MDMA-for-PTSD CRL still casts shadow over FDA-psychedelic interface
atai’s REMS strategy and trial design explicitly built to avoid those pitfalls, but regulatory uncertainty premium remains priced in
For mental health startups: bar for “interesting to a strategic” = proprietary mechanism + clean clinical data + capital efficiency

AtaiBeckley is the bet that interventional psychiatry’s Phase 3 era will produce real approvals, not the bet that psychedelics are inevitable
Beckley merger removed main competing platform; non-COMPASS pipeline now consolidated under one ticker
Non-hallucinogenic 5-HT2A program is the most interesting hedge in psychedelic biotech
Only program that survives if FDA decides REMS-heavy psychedelic approvals aren’t workable at scale
2029 Phase 3 timeline is the real story; every capital, governance, operational decision = “can we survive to 2029 without dilutive raises at unfavorable prices”
COMPASS liquidation + Bitcoin + NIDA grant + Psilera IP stack all point to non-dilutive funding as strategic priority, not side project
Psychedelic biotech is no longer a private market category; public companies absorbed credible IP and clinical infrastructure
Remaining private opportunity is in adjacencies: delivery models, REMS infrastructure, real-world evidence, non-hallucinogenic discovery
Single most important number in this 10-Q isn’t financial: it’s “early 2029” for BPL-003 Phase 3 topline; everything else is runway management to get there